Hydrocephalus

Post-traumatic hydrocephalus after decompressive craniectomy: a multidimensional analysis of clinical, radiological, and surgical risk factors

by

In a retrospective observational cohort study Romualdo et al. from the Department of Neurosurgery Faculty of Medicine, Technische Universität Dresden University Hospital Carl Gustav Carus published in the Neurosurgical Review to identify clinical, radiological, and surgical risk factors associated with the development of shunt-dependent posttraumatic hydrocephalus (PTH) in patients who underwent decompressive craniectomy following severe traumatic brain injury (TBI). Shunt-dependent post-traumatic hydrocephalus (PTH) occurred in 27% of patients after decompressive craniectomy for severe TBI. Independent risk factors included older age, basal cistern subarachnoid hemorrhage, post-traumatic ischemic infarcts, transcalvarial herniation, subdural hygroma, and progressive contusion hemorrhages. Surgical parameters were not predictive. Patients requiring shunt placement had significantly worse neurological outcomes 5).

🚨 The Illusion of Multidimensionality Despite claiming a “multidimensional” analysis, the study delivers a monotonous list of obvious associations—many of which have been reported in the literature for over a decade. Subarachnoid hemorrhage, infarction, hygroma, contusion progression… yes, thank you, we knew that. What’s new? Almost nothing.

Read more

Multi‑omics analysis of druggable genes to facilitate Alzheimer’s disease therapy: A multi‑cohort machine learning study

by

In a computational, multi-omics, machine learning study, Hu et al., published in the Journal of Prevention of Alzheimer’s Disease, aimed to identify druggable genes associated with Alzheimer’s disease (AD) by integrating multi-omics data from brain and blood samples and applying advanced machine learning and Mendelian randomization techniques to facilitate the development of effective therapeutic targets.

They concluded that LIMK2 is a promising druggable gene target for Alzheimer’s disease (AD), as its expression is significantly associated with key AD biomarkers — including Cerebrospinal fluid amyloid-beta, p-tau, and hippocampal atrophy — across both brain and blood datasets.

1)

Takeaway Message for a Neurosurgeon

Despite its computational complexity, the study by Hu et al. offers no clinically actionable insight for neurosurgeons. While it identifies LIMK2 as a statistically associated gene in Alzheimer’s pathology, there is no mechanistic evidence, no surgical relevance, and no translational pathway that justifies changing diagnostic or therapeutic strategies. Use it as a reminder: Data mining ≠ disease understanding. For neurosurgeons, especially those navigating cognitive decline in surgical candidates, CSF biomarkers and omics correlations remain tools — not decisions.

1. Conceptual Inflation Disguised as Innovation

The article by Hu et al. promises a “multi-cohort, multi-omics, machine learning” roadmap to druggable targets in Alzheimer’s disease (AD), but ultimately delivers a statistical Rube Goldberg machine — impressive in complexity, hollow in clinical consequence. The central narrative is built around the identification of “druggable genes” like LIMK2, but without a mechanistic framework, experimental validation, or translational bridge. The result is computational theater masquerading as biological discovery.

Read more